altRx Review: $89 and $149 Offers, Care Providers and Payment Rules

altRx advertises compounded semaglutide at $89 per month and compounded tirzepatide at $149 per month. Those figures were visible on its public product pages when we rendered them on October 15, 2026. The important qualification is that its cancellation policy makes the payment—not the shipment—the key commitment point.

The website also separates several parties behind the altRx name: a platform operator, a clinical practice network and independent dispensing pharmacies. This review follows those names, the published payment rules and the FDA’s June 2026 warning letter. We did not complete an assessment or checkout, so the headlines are advertised offers rather than a verified personalized total.

Who provides care, and who prepares the prescription?

The May 6, 2026 terms identify OpenLoop Health, Inc. as the platform operator and describe altRx as providing nonclinical marketing and support. The home-page disclosure identifies OpenLoop Healthcare Partners, PC and affiliated professional medical practices as the medical-service providers. These names describe different functions; the clinician’s practice and the pharmacy should also appear in the paperwork for an actual order.

altRx’s FAQ lists RedRock Pharmacy, Health Warehouse, Precision Medicine and Triad Rx among its network pharmacies. It describes independent, state-licensed compounding pharmacies. We have not audited those licenses or established which location would fill a particular prescription. A network list does not mean the marketing company compounds medication or that all patients receive an identical formulation.

The FAQ says membership is available in all 50 states, with provider availability and prescribing authority varying by state. It describes either live video or an asynchronous clinical review, depending on the provider and applicable requirements. The company’s availability statement is not a guarantee of individual eligibility, an issued prescription or a particular pharmacy assignment.

What the $89 and $149 pages do—and do not—show

The pages advertise no price increase and the home page says there is no separate membership fee. The legal policy nevertheless calls the purchase a subscription or membership bundle. Those labels do not establish an additional fee, but they do establish recurring-program rules. We did not verify the final checkout, so we do not multiply the headline by 12 and present the result as an annual quote.

The home page describes self-pay care without an insurance requirement and also lists branded products, including Wegovy and Zepbound. The compounded product headlines should not be carried over to branded prescriptions. Ask which exact product is being quoted and whether the payment schedule corresponds to one shipment, several shipments or a longer access period.

Cancellation stops future billing; it does not undo payment

The August 25, 2026 policy says payments become final at purchase, including unused or unshipped portions of a multi-month bundle. Not completing intake or receiving a prescription does not, by itself, create a refund right under that policy. This is materially more restrictive than assuming there is a cancellation window until the pharmacy ships.

To stop the next charge, the policy requires cancellation at least 72 hours before billing through care@altrx.com, +1 607-601-6969 or the patient portal where available. A later request takes effect after the upcoming cycle, whose charge remains nonrefundable. Record the actual billing date; a delivery estimate cannot identify this deadline.

The stated exception is provider-initiated medical disqualification. Even then, the policy deducts services already used, such as clinical review, issued prescriptions, medication and applicable lab services, from any unused-term refund. Damaged or incorrect items are addressed through replacement rather than a promised refund. These are the company’s terms, not our conclusion about any individual dispute or statutory rights.

The FDA warning letter is part of the record

On June 8, 2026, FDA issued warning letter 728236 to Trinity HealthCare Supply, LLC doing business as altRx, following a May website review. The agency objected to branding that suggested altRx was the compounder and to clinical claims that implied its compounded products had been evaluated or approved like approved medicines. The letter concerns marketing and labeling representations; it is not a laboratory test of a patient’s vial.

The current home-page disclosures explicitly say altRx does not manufacture or compound medication and that compounded products are not FDA approved. That current wording is relevant, but it does not demonstrate that FDA closed the matter. We have not established a closeout or other resolution. Readers can compare the dated letter with the present disclosures through the sources below.

Treat results and delivery estimates as company claims

The home page attributes its outcome figures to self-reported member information and notes that some testimonial endorsers are paid. It does not present those figures as a controlled, independently reviewed study of the program. Our rendered semaglutide page also exposed an editorial instruction asking whether a claim represented altRx patients or clinical data. That unresolved copy is a reason to ask for the specific supporting evidence before relying on a result claim.

The FAQ describes roughly four to five business days for processing and delivery. Elsewhere, the terms describe timing as dependent on verification, pharmacy work and carrier conditions. The site advertises round-the-clock access to support, but access to a message channel is not a response-time guarantee. We did not test support, delivery performance or the company’s patient-count claim.

A pharmacy checklist before committing

• Confirm the actual prescribing practice, assigned pharmacy and contact for label or storage questions.
• Save the full amount, term, renewal date and 72-hour cancellation deadline before paying.
• Ask how any medical-disqualification deduction is calculated before treating it as a full-refund promise.
• Request the evidence behind an outcome claim rather than assuming branded-drug research validates the dispensed compound.

altRx’s public pricing is more visible than BetterMe’s incomplete quote, but visibility does not make the commitment reversible. Its payment-final rule deserves equal weight with the low headline. Use our label and paperwork guide to keep the pharmacy, prescription and billing records distinct. Questions about whether a medicine is appropriate belong with a licensed clinician; this review evaluates public offer terms, not treatment suitability.